Referências
Principais artigos
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients - guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13512. Resumo
HIV.gov, US National Institutes of Health. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Jul 2021 [internet publication].Texto completo
HIV.gov, US National Institutes of Health. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. Aug 2023 [internet publication].Texto completo
Kotton CN, Kumar D, Caliendo AM, et al; The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018 Jun;102(6):900-31.Texto completo Resumo
Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017 Jun;17(6):e177-88.Texto completo Resumo
Artigos de referência
1. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients - guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13512. Resumo
2. HIV.gov, US National Institutes of Health. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Jul 2021 [internet publication].Texto completo
3. Ssentongo P, Hehnly C, Birungi P, et al. Congenital cytomegalovirus infection burden and epidemiologic risk factors in countries with universal screening: a systematic review and meta-analysis. JAMA Netw Open. 2021 Aug 2;4(8):e2120736.Texto completo Resumo
4. Hayward GS, Ambinder R, Ciufo D, et al. Structural organization of human herpesvirus DNA molecules. J Invest Dermatol. 1984 Jul;83(1 suppl):29s-41s. Resumo
5. Ayre K, Warren BF, Jeffery K, et al. The role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohns Colitis. 2009 Sep;3(3):141-8. Resumo
6. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008 Jul 23;300(4):413-22.Texto completo Resumo
7. Fowler KB, Boppana SB. Congenital cytomegalovirus infection. Semin Perinatol. 2018 Apr;42(3):149-54. Resumo
8. Devakumar D, Bamford A, Ferreira MU, et al. Infectious causes of microcephaly: epidemiology, pathogenesis, diagnosis, and management. Lancet Infect Dis. 2018 Jan;18(1):e1-13. Resumo
9. Boppana SB, Ross SA, Fowler KB. Congenital cytomegalovirus infection: clinical outcome. Clin Infect Dis. 2013 Dec;57 Suppl 4(suppl 4):S178-81.Texto completo Resumo
10. Revello M. Pathogenesis and prenatal diagnosis of congenital cytomegalovirus infection. J Clin Virol. 2004 Feb;29(2):71-83. Resumo
11. Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019 May;29(3):e2034. Resumo
12. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010 Jun 1;50(11):1439-47.Texto completo Resumo
13. Fowler K, Mucha J, Neumann M, et al. A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health. 2022 Sep 1;22(1):1659.Texto completo Resumo
14. Gantt S, Dionne F, Kozak FK, et al. Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection. JAMA Pediatr. 2016 Dec 1;170(12):1173-80.Texto completo Resumo
15. Kijpittayarit S, Eid AJ, Brown RA, et al. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis. 2007 May 15;44(10):1315-20. Resumo
16. Compton T, Kurt-Jones EA, Boehme KW, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD4 and Toll-like receptor 2. J Virol. 2003 Apr;77(8):4588-96.Texto completo Resumo
17. Einsele H, Kapp M, Grigoleit GU. CMV-specific T cell therapy. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):71-5. Resumo
18. Hernandez C, Mabilangan C, Burton C, et al. Cytomegalovirus transmission in mismatched solid organ transplant recipients: are factors other than anti-viral prophylaxis at play? Am J Transplant. 2021 Dec;21(12):3958-70.Texto completo Resumo
19. Helanterä I, Schachtner T, Hinrichs C, et al. Current characteristics and outcome of cytomegalovirus infections after kidney transplantation. Transpl Infect Dis. 2014 Aug;16(4):568-77. Resumo
20. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001 Dec 1;184(11):1461-4. Resumo
21. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004 Mar 15;103(6):2003-8. Resumo
22. Tedesco-Silva H, Felipe C, Ferreira A, et al. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant. 2015 Oct;15(10):2655-64.Texto completo Resumo
23. Chavarot N, Divard G, Scemla A, et al. Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. Am J Transplant. 2021 Jul;21(7):2448-58.Texto completo Resumo
24. Tedesco-Silva H, Pascual J, Viklicky O, et al. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study. Transplantation. 2019 Sep;103(9):1953-63.Texto completo Resumo
25. Kaminski H, Kamar N, Thaunat O, et al. Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: a randomized, open-label, multicenter phase 4 trial. Am J Transplant. 2022 May;22(5):1430-41.Texto completo Resumo
26. Weng MT, Tung CC, Lee YS, et al. Cytomegalovirus colitis in hospitalized inflammatory bowel disease patients in Taiwan: a referral center study. BMC Gastroenterol. 2017 Feb 13;17(1):28.Texto completo Resumo
27. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm. 2005 Apr 15;62(8 suppl 1):S7-13. Resumo
28. Kenneson A, Cannon MJ. Review and meta-analysis of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007 Jul-Aug;17(4):253-76. Resumo
29. Boucoiran I, Yudin M, Poliquin V, et al. Guideline No. 420: Cytomegalovirus infection in pregnancy. J Obstet Gynaecol Can. 2021 Jul;43(7):893-908. Resumo
30. American College of Obstetricians and Gynecologists. Practice bulletin no. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Jun 2015 [internet publication].
31. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003 May 15;101(10):4195-200.Texto completo Resumo
32. HIV.gov, US National Institutes of Health. Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV. Aug 2023 [internet publication].Texto completo
33. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002 Apr 15;34(8):1094-7.Texto completo Resumo
34. Razonable RR, Åsberg A, Rollag H, et al. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis. 2013 Jun;56(11):1546-53.Texto completo Resumo
35. Preiksaitis JK, Hayden RT, Tong Y, et al. Are we there yet? Impact of the first International Standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis. 2016 Sep 1;63(5):583-9. Resumo
36. Alsanea MS, Al-Qahtani AA, Almaghrabi RS, et al. Diagnosis of human cytomegalovirus drug resistance mutations in solid organ transplant recipients-a review. Diagnostics (Basel). 2024 Jan 18;14(2):203.Texto completo Resumo
37. Eid AJ, Bakri SJ, Kijpittayarit S, et al. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis. 2008 Feb;10(1):13-8. Resumo
38. Shreeniwas R, Schulman LL, Berkmen YM, et al. Opportunistic bronchopulmonary infections after lung transplantation: clinical and radiographic findings. Radiology. 1996 Aug;200(2):349-56. Resumo
39. Franquet T, Lee KS, Müller NL. Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS. AJR Am J Roentgenol. 2003 Oct;181(4):1059-63.Texto completo Resumo
40. Manuel O, Meylan PR, Rotman S, et al. Oral valganciclovir for cytomegalovirus colitis after liver transplantation. Transplantation. 2007 Jan 27;83(2):239-40.Texto completo
41. Ljungman P, Boeckh M, Hirsch HH, et al; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017 Jan 1;64(1):87-91. Resumo
42. Razonable RR, Paya CV, Smith TF. Role of the laboratory in the diagnosis and management of cytomegalovirus infection in hematopoietic and solid organ transplant recipients. J Clin Microbiol. 2002 Mar;40(3):746-52.Texto completo Resumo
43. Wohl DA, Kendall MA, Andersen J, et al; A5030 Study Team. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials. 2009 May-Jun;10(3):143-52.Texto completo Resumo
44. Boppana SB, Rivera LB, Fowler KB, et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001 May 3;344(18):1366-71.Texto completo Resumo
45. Donner C, Liesnard C, Brancart F, et al. Accuracy of amniotic fluid testing before 21 weeks' gestation in prenatal diagnosis of congenital cytomegalovirus infection. Prenat Diagn. 1994 Nov;14(11):1055-9. Resumo
46. Michaels MG, Greenberg DP, Sabo DL, et al. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatric Infect Dis J. 2003 Jun;22(6):504-9. Resumo
47. Lagasse N, Dhooge I, Govaert P, et al. Congenital CMV infections and hearing loss. Acta Otorhinolaryngology Belg. 2000;54(4):431-6. Resumo
48. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006 Feb;6(2):262-74.Texto completo Resumo
49. Chemaly RF, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019 Apr 8;68(8):1420-26.Texto completo Resumo
50. Centers for Disease Control and Prevention. Congenital cytomegalovirus (cCMV) infection and disease: 2024 case definition. Feb 2024 [internet publication].Texto completo
51. Kotton CN, Kumar D, Caliendo AM, et al; The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018 Jun;102(6):900-31.Texto completo Resumo
52. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007 Sep;7(9):2106-13. Resumo
53. Muller M, Wandel S, Colebunders R, et al; IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010 Apr;10(4):251-61. Resumo
54. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis. 1993 Dec;168(6):1506-9. Resumo
55. Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2022 Sep 10;75(4):690-701.Texto completo Resumo
56. Papanicolaou GA, Avery RK, Cordonnier C, et al. Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir. Clin Infect Dis. 2024 Mar 20;78(3):562-72.Texto completo Resumo
57. Razonable RR. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. Clin Microbiol Infect. 2023 Sep;29(9):1144-9. Resumo
58. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017 Jun;17(6):e177-88.Texto completo Resumo
59. Kimberlin DW, Jester PM, Sánchez PJ, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015 Mar 5;372(10):933-43.Texto completo Resumo
60. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003 Jul;143(1):16-25. Resumo
61. Oliver SE, Cloud GA, Sánchez PJ, et al; National Institute of Allergy, Infectious Diseases Collaborative Antiviral Study Group. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol. 2009 Dec;(46 suppl 4):S22-6. Resumo
62. Bonaros N, Mayer B, Schachner T, et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant. 2008 Jan-Feb;22(1):89-97. Resumo
63. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009 Mar 19;360(12):1191-9.Texto completo Resumo
64. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011 Apr 9;377(9773):1256-63.Texto completo Resumo
65. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012 Apr;12(4):290-9. Resumo
66. Vincenti F, Budde K, Merville P, et al. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. Am J Transplant. 2018 Dec;18(12):2945-54.Texto completo Resumo
67. Nakamura R, La Rosa C, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016 Feb;3(2):e87-98.Texto completo Resumo
68. Das R, Blázquez-Gamero D, Bernstein DI, et al. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Infect Dis. 2023 Dec;23(12):1383-94. Resumo
69. Scheinberg P, Melenhorst JJ, Brenchley JM, et al. The transfer of adaptive immunity to cytomegalovirus (CMV) during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood. 2009 Dec 3;114(24):5071-80. Resumo
70. Snyder LD, Chan C, Kwon D, et al. Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 2016 Jan 1;193(1):78-85. Resumo
71. Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013 Mar;56(6):817-24.Texto completo Resumo
72. Chen S, Pawelec G, Trompet S, et al. Associations of cytomegalovirus infection with all-cause and cardiovascular mortality in multiple observational cohort studies of older adults. J Infect Dis. 2021 Feb 3;223(2):238-46.Texto completo Resumo
73. Manuel O, Kralidis G, Mueller NJ, et al; Swiss Transplant Cohort Study. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2013 Sep;13(9):2402-10.Texto completo Resumo
74. Martin-Gandul C, Mueller NJ, Pascual M, et al. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant. 2015 Dec;15(12):3024-40Texto completo Resumo
75. American Society of Transplantation, American Society of Transplant Surgeons. Cytomegalovirus. Am J Transplant. 2004;4(suppl 10):51-8.Texto completo
76. Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant. 2005 Feb;5(2):218-27.Texto completo Resumo
77. Portillo V, Masouridi-Levrat S, Royston L, et al. Revisiting cytomegalovirus serology in allogeneic hematopoietic cell transplant recipients. Clin Infect Dis. 2024 Feb 17;78(2):423-9.Texto completo Resumo
78. Vernooij RW, Michael M, Ladhani M, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2024 May 3;5(5):CD003774. Resumo
79. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 1996 Jun 6;334(23):1491-7.Texto completo Resumo
80. Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 1998 Feb 12;12(3):269-77. Resumo
81. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017 Dec 21;377(25):2433-44.Texto completo Resumo
82. Royston L, Royston E, Masouridi-Levrat S, et al. Letermovir primary prophylaxis in high-risk hematopoietic cell transplant recipients: a matched cohort study. Vaccines (Basel). 2021 Apr 12;9(4):372.Texto completo Resumo
83. Limaye AP, Budde K, Humar A, et al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA. 2023 Jun 6;e239106.Texto completo Resumo
84. Shahar-Nissan K, Pardo J, Peled O, et al. Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial. Lancet. 2020 Sep 12;396(10253):779-85. Resumo
85. Chatzakis C, Shahar-Nissan K, Faure-Bardon V, et al. The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis. Am J Obstet Gynecol. 2024 Feb;230(2):109-17.e2. Resumo
86. Revello MG, Lazzarotto T, Guerra B, et al; CHIP Study Group. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014 Apr 3;370(14):1316-26.Texto completo Resumo
87. Hughes BL, Clifton RG, Rouse DJ, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. A trial of hyperimmune globulin to prevent congenital cytomegalovirus infection. N Engl J Med. 2021 Jul 29;385(5):436-44. Resumo
88. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005 Dec 20;143(12):870-80. Resumo
89. Small LN, Lau J, Snydman DR. Preventing post-organ transplant cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis. 2006 Oct 1;43(7):869-80. Resumo
90. Strippoli GF, Hodson EM, Jones C, et al. Preemptive treatment of cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation. 2006 Jan 27;81(2):139-45. Resumo
91. Owers DS, Webster AC, Strippoli GF, et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;(2):CD005133.Texto completo Resumo
92. Singh N, Winston DJ, Razonable RR, et al. Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial. JAMA. 2020 Apr 14;323(14):1378-87.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal